OrbiMed’s Achillion Pharmaceuticals ACHN Stock Holding History

OrbiMed’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-200,000	Closed	-$1.54M	–	150
2016 Q1	$1.54M	Buy	+200,000	New	+$1.46M	0.02%	132

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

OrbiMed's ACHN Position: Q1 2018 in Review

OrbiMed sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 8,170,973 shares — an estimated $23.5M sold.

OrbiMed first reported a position in ACHN in Q2 2013 and held it in 14 quarters. The position peaked at $106M in Q3 2016. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

OrbiMed reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
OrbiMed sold 8,170,973 Achillion Pharmaceuticals shares in Q1 2018, an estimated $23.5M.
OrbiMed first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
OrbiMed's Achillion Pharmaceuticals position peaked at $106M in Q3 2016.
127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.